Jerene, D., van Kalmthout, K., Levy, J., Alacapa, J., Deyanova, N., Dube, T., Mganga, A., Tasca, B., Bogdanov, A., Efo, E. and Gamazina, K., 2025. Effect of digital adherence technologies on treatment outcomes in people with drug-susceptible tuberculosis: four pragmatic, cluster-randomised trials. The Lancet.

Borges, Á.H. et al. (2025) ‘Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV‐negative adults successfully treated for drug‐susceptible pulmonary tuberculosis: a double‐blind, randomised, placebo‐controlled, phase 2b trial’, Lancet Infectious Diseases, Published online 5 March 2025. doi:10.1016/S1473-3099(24)00814-4.

Wahome, E., Otieno, F.O., Kimani, J., Boyd, A., Okall, D., Nzioka, J., Gichuru, E., van der Elst, E., Mehta, S.D., Bailey, R.C. and Graham, S.M., 2022. Impact of COVID-19-related clinic closures on HIV incidence in a multicentre study of young adult MSM and transgender women in Kenya. AIDS, pp.10-1097.

Chihota, V., Gombe, M., Gupta, A., Salazar-Austin, N., Ryckman, T., Hoffmann, C.J., LaCourse, S., Mathad, J.S., Mave, V., Dooley, K.E. and Chaisson, R.E., 2024. Tuberculosis Preventive Treatment in High TB-Burden Settings: A State-of-the-Art Review. Drugs, pp.1-21.